These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28176046)

  • 1. Critical Evaluation of Animal Models of Gastrointestinal Disorders.
    Johnson AC; Greenwood-Van Meerveld B
    Handb Exp Pharmacol; 2017; 239():289-317. PubMed ID: 28176046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastrointestinal Physiology and Function.
    Greenwood-Van Meerveld B; Johnson AC; Grundy D
    Handb Exp Pharmacol; 2017; 239():1-16. PubMed ID: 28176047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists.
    Sanger GJ; Wang Y; Hobson A; Broad J
    Br J Pharmacol; 2013 Dec; 170(7):1323-32. PubMed ID: 23189978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are We Close to Targeting Enteric Glia in Gastrointestinal Diseases and Motility Disorders?
    Gulbransen BD; Christofi FL
    Gastroenterology; 2018 Aug; 155(2):245-251. PubMed ID: 29964042
    [No Abstract]   [Full Text] [Related]  

  • 5. The enteric nervous system III: a target for pharmacological treatment.
    Hansen MB
    Pharmacol Toxicol; 2003 Jul; 93(1):1-13. PubMed ID: 12828568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Bioelectronics in the Gastrointestinal Tract.
    Miller L; Farajidavar A; Vegesna A
    Cold Spring Harb Perspect Med; 2019 Sep; 9(9):. PubMed ID: 30249600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electrical therapies for gastrointestinal motility disorders.
    Chen JD; Yin J; Wei W
    Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):407-418. PubMed ID: 28277856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upper GI Disorders: Pathophysiology and Current Therapeutic Approaches.
    Parkman HP
    Handb Exp Pharmacol; 2017; 239():17-37. PubMed ID: 28105529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormones of the gut-brain axis as targets for the treatment of upper gastrointestinal disorders.
    Sanger GJ; Lee K
    Nat Rev Drug Discov; 2008 Mar; 7(3):241-54. PubMed ID: 18309313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuromodulators for Functional Gastrointestinal Disorders (Disorders of Gut-Brain Interaction): A Rome Foundation Working Team Report.
    Drossman DA; Tack J; Ford AC; Szigethy E; Törnblom H; Van Oudenhove L
    Gastroenterology; 2018 Mar; 154(4):1140-1171.e1. PubMed ID: 29274869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.
    Katzka DA; Loftus EV; Camilleri M
    Clin Pharmacol Ther; 2012 Sep; 92(3):306-20. PubMed ID: 22828717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment of functional bowel disorders: any light at the end of the tunnel?
    Boeckxstaens GE
    Curr Opin Pharmacol; 2008 Dec; 8(6):669-70. PubMed ID: 18835367
    [No Abstract]   [Full Text] [Related]  

  • 13. Emerging role of cyclooxygenase isoforms in the control of gastrointestinal neuromuscular functions.
    Fornai M; Antonioli L; Colucci R; Bernardini N; Ghisu N; Tuccori M; De Giorgio R; Del Tacca M; Blandizzi C
    Pharmacol Ther; 2010 Jan; 125(1):62-78. PubMed ID: 19808045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.
    Konturek PC; Brzozowski T; Konturek SJ
    J Physiol Pharmacol; 2011 Dec; 62(6):591-9. PubMed ID: 22314561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonruminant Nutrition Symposium: Involvement of gut neural and endocrine systems in pathological disorders of the digestive tract.
    Furness JB; Poole DP
    J Anim Sci; 2012 Apr; 90(4):1203-12. PubMed ID: 22178854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The enteric nervous system].
    Hansen MB
    Ugeskr Laeger; 2003 Oct; 165(43):4097-101. PubMed ID: 14619057
    [No Abstract]   [Full Text] [Related]  

  • 17. Drugs targeting functional bowel disorders: insights from animal studies.
    Sanger GJ; Hicks GA
    Curr Opin Pharmacol; 2002 Dec; 2(6):678-83. PubMed ID: 12482730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome.
    Camilleri M
    Clin Pharmacol Ther; 2012 Jan; 91(1):44-59. PubMed ID: 22071696
    [No Abstract]   [Full Text] [Related]  

  • 19. Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance.
    Terry N; Margolis KG
    Handb Exp Pharmacol; 2017; 239():319-342. PubMed ID: 28035530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The gastrointestinal pharmacology of cannabinoids: focus on motility.
    Abalo R; Vera G; López-Pérez AE; Martínez-Villaluenga M; Martín-Fontelles MI
    Pharmacology; 2012; 90(1-2):1-10. PubMed ID: 22699400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.